Cogent Biosciences Past Earnings Performance
Past criteria checks 0/6
Cogent Biosciences's earnings have been declining at an average annual rate of -24.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 93.5% per year.
Key information
-24.9%
Earnings growth rate
28.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -93.5% |
| Return on equity | -77.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04
Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09Revenue & Expenses Breakdown
How Cogent Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -242 | 41 | 219 |
| 30 Jun 24 | 0 | -227 | 39 | 206 |
| 31 Mar 24 | 0 | -212 | 37 | 190 |
| 31 Dec 23 | 0 | -192 | 34 | 174 |
| 30 Sep 23 | 0 | -178 | 32 | 162 |
| 30 Jun 23 | 0 | -157 | 29 | 142 |
| 31 Mar 23 | 0 | -148 | 27 | 132 |
| 31 Dec 22 | 0 | -140 | 26 | 122 |
| 30 Sep 22 | 0 | -126 | 24 | 105 |
| 30 Jun 22 | 0 | -110 | 22 | 111 |
| 31 Mar 22 | 0 | -91 | 21 | 81 |
| 31 Dec 21 | 0 | -72 | 20 | 56 |
| 30 Sep 21 | 0 | -163 | 20 | 35 |
| 30 Jun 21 | 0 | -194 | 20 | 0 |
| 31 Mar 21 | 1 | -185 | 18 | 0 |
| 31 Dec 20 | 8 | -179 | 17 | 0 |
| 30 Sep 20 | 23 | -61 | 15 | 0 |
| 30 Jun 20 | 24 | -23 | 12 | 0 |
| 31 Mar 20 | 26 | -27 | 12 | 0 |
| 31 Dec 19 | 22 | -32 | 11 | 0 |
Quality Earnings: COGT is currently unprofitable.
Growing Profit Margin: COGT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COGT is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare COGT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COGT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: COGT has a negative Return on Equity (-77%), as it is currently unprofitable.